Nonsynonymous base changes identified by exonic resequencing of DNAs from 94 AML patients. Unique patient numbers (UPNs) are shown in the rows, and the names of sequenced genes are shown in the columns. T indicates tumor (sequence variants in the AML tumor sample); G, germline (sequence variants in the “germline” (skin) sample from the same patient). Green indicates that no nonsynonymous sequence variants were identified in that sample; red identifies samples with nonsynonymous variants; the predicted consequences of all sequence variants detected are listed; yellow indicates the presence of a homozygous sequence variant; white boxes indicate that no sequence was obtained. All somatic mutations were confirmed by automated resequencing and/or hand validation. No nonsynonymous sequence variants were detected in FES, LYN, YES1, BTK, PTK2B, IGF1R, SYK, RYK, or CSK (data not shown). Mutations found in FLP3, KIT, N-RAS, KRAS, and PTPN11 are exactly the same as described previously.²⁰  The nonsynonymous sequence variants shown for FGR (D230V) and FYN (D502E) are known to be SNPs and therefore were not sequenced in the skin samples.